Camber Capital Management’s Ascendis Pharma A/S ASND Stock Holding History

Camber Capital Management’s Portfolio ASND Stock Details ASND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	$43.1M	Sell	250,000 -100,000	-29%	-$16.3M	4.05%	8
2025 Q1	$54.6M	Sell	350,000 -450,000	-56%	-$64.3M	1.94%	14
2024 Q4	$110M	Buy	800,000 +100,000	+14%	+$13.1M	2.55%	14
2024 Q3	$105M	Buy	+700,000	New	+$94.5M	3.32%	11
2024 Q1	–	Sell	-165,000	Closed	-$20.8M	–	37
2023 Q4	$20.8M	Buy	+165,000	New	+$16.5M	0.53%	30
2020 Q3	–	Sell	-350,000	Closed	-$51.8M	–	36
2020 Q2	$51.8M	Sell	350,000 -186,710	-35%	-$25.6M	2.96%	12
2020 Q1	$60.4M	Sell	536,710 -126,290	-19%	-$16.4M	3.61%	13
2019 Q4	$92.2M	Buy	663,000 +13,000	+2%	+$1.44M	4.69%	7
2019 Q3	$62.6M	Hold	650,000	–	–	3.29%	14
2019 Q2	$74.8M	Buy	650,000 +220,000	+51%	+$26.3M	3.49%	12
2019 Q1	$50.6M	Buy	+430,000	New	+$37.7M	2.52%	18

Other funds holding ASND

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Camber Capital Management's ASND Position: Q2 2025 in Review

Camber Capital Management reduced its Ascendis Pharma A/S (ASND) stake by 29% in Q2 2025, selling an estimated $16.3M and leaving 250,000 shares worth $43.1M. The position accounts for 4.05% of the portfolio, ranked #8.

Camber Capital Management first reported a position in ASND in Q1 2019 and has held it in 11 quarters since. The position peaked at $110M in Q4 2024. 247 funds tracked by Wall St. Rank hold ASND as of Q2 2025.

Camber Capital Management held 250,000 shares of Ascendis Pharma A/S worth $43.1M as of Q2 2025.
Camber Capital Management sold 100,000 Ascendis Pharma A/S shares in Q2 2025, an estimated $16.3M.
Ascendis Pharma A/S made up 4.05% of Camber Capital Management's portfolio in Q2 2025, its #8 holding.
Camber Capital Management first reported a position in Ascendis Pharma A/S in Q1 2019 and has held it in 11 quarters since.
Camber Capital Management's Ascendis Pharma A/S position peaked at $110M in Q4 2024.
247 funds tracked by Wall St. Rank held Ascendis Pharma A/S as of Q2 2025.

Based on Camber Capital Management's 13F filing for Q2 2025, filed 14 Aug 2025.